The FDA awarded Magstim, a Carmarthenshire, Wales firm, clearance to bring to market the company’s Magstim Rapid2 rTMS (repetitive Transcranial Magnetic Stimulation) Therapy System. The system is indicated to treat drug resistant major depressive disorder in an outpatient setting.
The Magstim Rapid2 has been available to researchers in fields such as cognitive neuroscience, neurophysiology, and rehabilitation. Now the magnetic stimulator will be available in the U.S. as a clinical product.
It’s intended to target the dorsolateral left pre-frontal cortex (DLPFC), a region of the brain that sees reduced blood flow in patients with serious depression. When magnetically stimulated, blood flow tends to increase, improving mood and reducing symptoms of the depression.
source:Magstim
Magstim’s Repetitive Transcranial Magnetic Stimulation Therapy System to Fight Major Depression
